ArticleBreast cancer (Dove Medical Press)2024

Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients.

Feng Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.